Latest & greatest articles for brimonidine

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on brimonidine or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on brimonidine and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for brimonidine

1. Brimonidine

Brimonidine Top results for brimonidine - Trip Database or use your Google+ account Find evidence fast My query is: English Français Deutsch Čeština Español Magyar Svenska ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search (...) button. An example search might look like (#1 or #2) and (#3 or #4) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for brimonidine The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory

Trip Latest and Greatest2018

2. Brimonidine gel (Mirvaso): risk of systemic cardiovascular effects; not to be applied to damaged skin

Brimonidine gel (Mirvaso): risk of systemic cardiovascular effects; not to be applied to damaged skin Brimonidine gel (Mirvaso): risk of systemic cardiovascular effects; not to be applied to damaged skin - GOV.UK GOV.UK uses cookies to make the site simpler. Search Brimonidine gel (Mirvaso): risk of systemic cardiovascular effects; not to be applied to damaged skin From: Published: 21 June 2017 Therapeutic area: and Systemic cardiovascular effects including bradycardia, hypotension, and (...) dizziness have been reported after application. It is important to avoid application to irritated or damaged skin, including after laser therapy. Advice for healthcare professionals: cases of bradycardia, hypotension (including orthostatic hypotension), and dizziness after application of brimonidine gel have been reported, some of which required hospitalisation some cases were associated with application of brimonidine gel after laser procedures to the skin, which possibly caused increased absorption

MHRA Drug Safety Update2017

3. Brimonidine gel (Mirvaso): risk of exacerbation of rosacea

Brimonidine gel (Mirvaso): risk of exacerbation of rosacea Brimonidine gel (Mirvaso): risk of exacerbation of rosacea - GOV.UK GOV.UK uses cookies to make the site simpler. Search Brimonidine gel (Mirvaso): risk of exacerbation of rosacea From: Published: 8 November 2016 Therapeutic area: Some patients may have exacerbation or rebound symptoms of rosacea. It is important to initiate treatment with a small amount of gel and increase the dose gradually, based on tolerability and treatment (...) response. Contents Advice for healthcare professionals: exacerbation of rosacea symptoms occurred in up to 16% of patients treated with brimonidine gel in clinical studies; in most cases, erythema and flushing resolve after stopping treatment initiate treatment with a small amount of gel (less than the maximum dose) for at least 1 week and increase the dose gradually, based on tolerability and response to treatment advise patients carefully on how to apply the gel and on the importance of not exceeding

MHRA Drug Safety Update2016

4. Brimonidine (Mirvaso®)

Brimonidine (Mirvaso®) Brimonidine (Mirvaso®) Brimonidine (Mirvaso®) All Wales Medicines Strategy Group (AWMSG) Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation All Wales Medicines Strategy Group (AWMSG). Brimonidine (Mirvaso®) Penarth: All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG). AWMSG (...) Secretariat Assessment Report Advice No. 2168. 2015 Authors' conclusions Brimonidine (Mirvaso®) is recommended for restricted use within NHS Wales for the symptomatic treatment of facial erythema of rosacea in adult patients. Brimonidine (Mirvaso®) should be restricted for use in patients with moderate to severe persistent facial erythema associated with rosacea. Brimonidine (Mirvaso®) is not recommended for use within NHS Wales outside of this subpopulation. Final publication URL Indexing Status Subject

Health Technology Assessment (HTA) Database.2015

5. Brimonidine (Mirvaso) - for the symptomatic treatment of facial erythema of rosacea

Brimonidine (Mirvaso) - for the symptomatic treatment of facial erythema of rosacea Final Appraisal Recommendation Advice No: 2015 – July 2015 Brimonidine (Mirvaso ® ) 3 mg/g gel Submission by Galderma (UK) Ltd In reaching the above recommendation AWMSG has taken account of the appraisal documentation prepared by the AWMSG Secretariat (reference number 2168), which includes the AWMSG Secretariat Assessment Report (ASAR), the Preliminary Appraisal Recommendation (PAR) and the applicant company’s (...) : brimonidine (Mirvaso ® ) 3 mg/g gel. July 2015. Recommendation of AWMSG Brimonidine (Mirvaso ® ) is recommended for restricted use within NHS Wales for the symptomatic treatment of facial erythema of rosacea in adult patients. Brimonidine (Mirvaso ® ) should be restricted for use in patients with moderate to severe persistent facial erythema associated with rosacea. Brimonidine (Mirvaso ® ) is not recommended for use within NHS Wales outside of this subpopulation.

All Wales Medicines Strategy Group2015

7. Glaucoma: brinzolamide/brimonidine combination eye drops

Glaucoma: brinzolamide/brimonidine combination eye drops Glaucoma: brinzolamide/brimonidine Glaucoma: brinzolamide/brimonidine combination e combination ey ye drops e drops Evidence summary Published: 17 March 2015 nice.org.uk/guidance/esnm56 pathways K Ke ey points from the e y points from the evidence vidence The content of this evidence summary was up-to-date in March 2015. See summaries of product characteristics (SPCs), British national formulary (BNF) or the MHRA or NICE websites for up (...) -to-date information. Summary In 2 randomised controlled trials in people with glaucoma, brinzolamide/brimonidine combination eye drops were statistically significantly superior to either constituent drug administered alone as monotherapy in reducing intraocular pressure at 3 months. The combination eye drops were non-inferior to brinzolamide plus brimonidine administered concomitantly. Most reported adverse events were mild to moderate and localised, but these were higher in number

National Institute for Health and Clinical Excellence - Advice2015

8. Brinzolamide and brimonidine (Simbrinza) - open-angle glaucoma or ocular hypertension

Brinzolamide and brimonidine (Simbrinza) - open-angle glaucoma or ocular hypertension Published 10 November 2014 Product Update: brinzolamide 10mg/mL and brimonidine tartrate 2mg/mL eye drops, suspension (Simbrinza ® ) (No: 991/14) Alcon Eye Care UK Ltd 08 August 2014 (Issued 10 October 2014) The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use in NHS Scotland. The advice (...) is summarised as follows: ADVICE: following an abbreviated submission brinzolamide / brimonidine tartrate eye drops, suspension (Simbrinza ® ) is accepted for use within NHS Scotland. Indication under review: decrease of elevated intraocular pressure (IOP) in adult patients with open-angle glaucoma or ocular hypertension for whom monotherapy provides insufficient IOP reduction. There is no significant additional cost associated with the combination product compared with the individual components

Scottish Medicines Consortium2014

9. Simbrinza - brinzolamide / brimonidine tartrate

Simbrinza - brinzolamide / brimonidine tartrate 7 Westferry Circus ? Canary Wharf ? London E14 4HB ? United Kingdom An agency of the European Union Telephone +44 (0)20 7418 8400 Facsimile +44 (0)20 7523 7455 E-mail info@ema.europa.eu Website www.ema.europa.eu 22 May 2014 EMA/366328/2014 Committee for Medicinal Products for Human Use (CHMP) Assessment report Simbrinza International non-proprietary name: Brinzolamide / Brimonidine tartrate Procedure No. EMEA/H/C/003698/0000 Note Assessment report (...) 73 2.6.1. Discussion on clinical safety 74 2.6.2. Conclusions on the clinical safety 76 2.7. Pharmacovigilance 77 2.8. Risk Management Plan 77 2.9. User consultation 78 3. Benefit-Risk Balance 79 4. Recommendations 83 Assessment report EMA/366328/2014 Page 4/83 List of abbreviations Abbreviation/Term Definition a2 Alpha 2 ADR Adverse drug reaction AE Adverse event AUC Area under the curve BAK Benzalkonium chloride BID Two times daily (Bis in Die) Brinz/Brim Brinzolamide /Brimonidine 10mg/mL + 2

European Medicines Agency - EPARs2014

10. Mirvaso - brimonidine

Mirvaso - brimonidine 7 Westferry Circus ? Canary Wharf ? London E14 4HB ? United Kingdom An agency of the European Union Telephone +44 (0)20 7418 8400 Facsimile +44 (0)20 7418 8416 E-mail info@ema.europa.eu Website www.ema.europa.eu © European Medicines Agency, 2014. Reproduction is authorised provided the source is acknowledged. 19 December 2013 EMA/CHMP/115246/2014 Committee for Medicinal Products for Human Use (CHMP) Assessment report Mirvaso International non-proprietary name: brimonidine (...) Procedure No. EMEA/H/C/002642/0000 Note Assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted. Assessment Report EMA/CHMP/115246/2014 Page 2/107 Product information Name of the medicinal product: Mirvaso Applicant: Galderma International Tour Europlaza, 20 avenue André Prothin – La Défense 4 La Défense Cedex 92927 France Active substance: Brimonidine tartrate International Nonproprietary Name: Brimonidine Pharmaco-therapeutic group (ATC Code): Other

European Medicines Agency - EPARs2014

11. Facial erythema of rosacea: brimonidine tartrate gel

Facial erythema of rosacea: brimonidine tartrate gel Facial erythema of rosacea: brimonidine tartr Facial erythema of rosacea: brimonidine tartrate ate gel gel Evidence summary Published: 8 July 2014 nice.org.uk/guidance/esnm43 pathways K Ke ey points from the e y points from the evidence vidence The content of this evidence summary was up-to-date in July 2014. See summaries of product characteristics (SPCs), British national formulary (BNF) or the MHRA or NICE websites for up- to-date (...) information. Summary In 2 short-term randomised controlled trials (RCTs: n=553) brimonidine tartrate gel was statistically significantly more effective than vehicle gel in reducing erythema in people with a clinical diagnosis of rosacea and moderate to severe erythema. However, 'success rates' (defined as a 2-grade reduction in the severity of erythema as assessed by both patients and clinicians) were just 25% to 30% with brimonidine gel compared with about 10% for vehicle gel at day 29. © NICE 2018. All

National Institute for Health and Clinical Excellence - Advice2014

12. Simbrinza (brinzolamide/brimonidine tartrate ophthalmic suspension)

Simbrinza (brinzolamide/brimonidine tartrate ophthalmic suspension) Drug Approval Package: SIMBRINZA (brinzolamide/brimonidine tartrate) NDA #204251 Drug Approval Package U.S. Food & Drug Administration Enter Search terms Drug Approval Package - SIMBRINZA (brinzolamide/brimonidine tartrate ophthalmic suspension), 1%/0.2% Company: Alcon Research, Ltd Application No.: 204251 Approval Date: 04/19/2013 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634

FDA - Drug Approval Package2013

13. Mirvaso (brimonidine) Topical Gel

Mirvaso (brimonidine) Topical Gel Drug Approval Package: Brand Name (Generic Name) NDA # Drug Approval Package U.S. Food & Drug Administration Enter Search terms Drug Approval Package - Mirvaso (brimonidine) Topical Gel Company: Galderma Research and Development Inc. Application No.: 204708 Approval Date: 8/23/2013 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance. (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF

FDA - Drug Approval Package2013

14. The efficacy and harm of prostaglandin analogues for IOP reduction in glaucoma patients compared to dorzolamide and brimonidine: a systematic review

The efficacy and harm of prostaglandin analogues for IOP reduction in glaucoma patients compared to dorzolamide and brimonidine: a systematic review The efficacy and harm of prostaglandin analogues for IOP reduction in glaucoma patients compared to dorzolamide and brimonidine: a systematic review The efficacy and harm of prostaglandin analogues for IOP reduction in glaucoma patients compared to dorzolamide and brimonidine: a systematic review Hodge W G, Lachaine J, Steffensen I, Murray C (...) , Barnes D, Foerster V, Ducruet T, Morrison A CRD summary This review concluded that latanoprost was superior to dorzolamide but not brimonidine. However, fewer adverse events were found for latanoprost than brimonidine. The authors' conclusions follow from the data presented, but are based on small data sets and as such some caution is advisable. Authors' objectives To assess the efficacy and safety of prostaglandin analogues (PGAs) compared to brimonidine and dorzolamide in people

DARE.2008

15. Meta-analysis of randomized controlled trials comparing timolol with brimonidine in the treatment of glaucoma

Meta-analysis of randomized controlled trials comparing timolol with brimonidine in the treatment of glaucoma Meta-analysis of randomized controlled trials comparing timolol with brimonidine in the treatment of glaucoma Meta-analysis of randomized controlled trials comparing timolol with brimonidine in the treatment of glaucoma Loon S C, Liew G, Fung A, Reid S E, Craig J C CRD summary The authors concluded that timolol and brimonidine were equally effective in lowering intraocular pressure (...) . Brimonidine was associated with a higher rate of allergy. The review was mostly well conducted but, in view of unexplained heterogeneity in the analyses, the authors' conclusions may need to be regarded with some caution. Authors' objectives To compare the efficacy and tolerability of timolol with brimonidine in the treatment of glaucoma. Searching The following databases were searched: MEDLINE (1966 to December 2006), EMBASE (1980 to December 2006), the Cochrane Central Register of Controlled Trials

DARE.2008

16. Costs and persistence of brimonidine versus brinzolamide in everyday glaucoma care: an analysis conducted on the UK General Practitioner Research Database

Costs and persistence of brimonidine versus brinzolamide in everyday glaucoma care: an analysis conducted on the UK General Practitioner Research Database Costs and persistence of brimonidine versus brinzolamide in everyday glaucoma care: an analysis conducted on the UK General Practitioner Research Database Costs and persistence of brimonidine versus brinzolamide in everyday glaucoma care: an analysis conducted on the UK General Practitioner Research Database Lafuma A, Laurendeau C, Berdeaux G (...) Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary The objective was to compare the persistence and costs of brimonidine versus brinzolamide. The authors concluded that brinzolamide was more persistent than brimonidine, with patients

NHS Economic Evaluation Database.2008

17. Meta-analysis of randomised controlled trials comparing latanoprost with brimonidine in the treatment of open-angle glaucoma, ocular hypertension or normal-tension glaucoma

Meta-analysis of randomised controlled trials comparing latanoprost with brimonidine in the treatment of open-angle glaucoma, ocular hypertension or normal-tension glaucoma Meta-analysis of randomised controlled trials comparing latanoprost with brimonidine in the treatment of open-angle glaucoma, ocular hypertension or normal-tension glaucoma Meta-analysis of randomised controlled trials comparing latanoprost with brimonidine in the treatment of open-angle glaucoma, ocular hypertension or (...) normal-tension glaucoma Fung A T, Reid S E, Jones M P, Healey P R, McCluskey P J, Craig J C CRD summary This review compared the effectiveness and adverse effects of latanoprost versus brimonidine for treating open-angle glaucoma, normal-tension glaucoma and ocular hypertension. The authors concluded that latanoprost is more effective in reducing intraocular pressure than brimonidine and that brimonidine causes more fatigue than latanoprost. The review was generally well-conducted and the conclusions

DARE.2007

18. Brimonidine Tartrate Ophthalmic Solution

Brimonidine Tartrate Ophthalmic Solution Drug Approval Package: Brimonidine Tartrate NDA #021764 Drug Approval Package U.S. Food & Drug Administration Enter Search terms Drug Approval Package - Brimonidine Tartrate Ophthalmic Solution Company: Alcon, Inc. Application No.: 021764 Approval Date: 05/22/2006 (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) Date created: February 22, 2008 Note: Documents in PDF format require the . - - Links on this page: Note: If you need help accessing

FDA - Drug Approval Package2006

20. brimonidine tartrate/timolol maleate

brimonidine tartrate/timolol maleate FINAL RECOMMENDATION and REASONS for RECOMMENDATION BRIMONIDINE TARTRATE/TIMOLOL MALEATE OPHTHALMIC SOLUTION (Combigan®—Allergan) Description: Brimonidine tartrate/timolol maleate ophthalmic solution is a combination ophthalmologic product containing a selective alpha-2 adrenergic agonist and a non-selective beta adrenergic receptor blocking agent. It is indicated for the control of intraocular hypertension in patients with chronic open-angle glaucoma or (...) ocular hypertension who are insufficiently responsive to intraocular pressure-reducing monotherapy and when the use of Combigan® is considered appropriate. Recommendation: CEDAC recommended that brimonidine tartrate/timolol maleate ophthalmic solution be recommended for listing for individuals who do not adequately respond to beta-blocking agents. Rationale for the recommendation: 1. Brimonidine tartrate/timolol maleate ophthalmic solution has similar intraocular pressure- lowering efficacy

Canadian Agency for Drugs and Technologies in Health - Common Drug Review2004